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Li Xu1,2, Yanli Wen1, Santosh Pandit2, Venkata R. S. S. Mokkapati2, Ivan Mijakovic2,3*, Yan Li1, Min Ding1, 
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Abstract 
Prostate cancer (PC) is the sixth most common cancer type in the world, which causes approximately 10% of total 
cancer fatalities. The detection of protein biomarkers in body fluids is the key topic for the diagnosis and prognosis of 
PC. Highly sensitive screening of PC is the most effective approach for reducing mortality. Thus, there are a growing 
number of literature that recognizes the importance of new technologies for early diagnosis of PC. Graphene is play-
ing an important role in the biosensor field with remarkable physical, optical, electrochemical and magnetic proper-
ties. Many recent studies demonstrated the potential of graphene materials for sensitive detection of protein bio-
markers. In this review, the graphene-based biosensors toward PC analysis are mainly discussed in two groups: Firstly, 
novel biosensor interfaces were constructed through the modification of graphene materials onto sensor surfaces. 
Secondly, ingenious signal amplification strategies were developed using graphene materials as catalysts or carriers. 
Graphene-based biosensors have exhibited remarkable performance with high sensitivities, wide detection ranges, 
and long-term stabilities.
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Introduction
PC is one of the most common cancers in the world 
which causes a fatality of approximately 10% in all can-
cer patients [1–4]. PC is a type of malignant neoplasm of 
the prostate gland which is extremely prevalent among 
men of age 50 and older [5, 6]. The established risk fac-
tors for PC include advancing age, race, positive family 
history of PC and diet [7, 8]. Being asymptomatic, it is 
very difficult to detect PC at early stages [9]. In clinical 
practice, early screening and diagnosis of PC is the most 
effective approach for reducing mortality [9, 10]. Thus, 
there is a growing body of literature that recognizes the 
importance of new technologies for early screening and 
diagnosis of PC [11, 12].
Tumor markers for early clinical screening and rapid 
diagnosis cover a wide range of biochemical entities, 
including, proteins [13, 14], nucleic acids [15–17], small 
metabolites [18, 19], cytogenetic and cytokinetic parame-
ters [20], and entire tumor cells [21, 22] in body fluid [23]. 
So far, protein biomarkers are still recognized as a golden 
standard for PC diagnosis [24]. In the past few decades, 
a variety of promising biosensors have been developed 
based on the specific recognition of PC protein biomark-
ers, aiming at better performance of cancer diagnosis 
such as easy operation, portability, and real-time analy-
sis [25–28]. Among them, the graphene-based biosen-
sors have received considerable critical attention for the 
potential use in point-to-care (POC) testing devices, 
because of the unique properties of graphene such as 
large surface area, high electrical conductivity, excellent 
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biocompatibility and convenient production/functionali-
zation [29–31].
This review highlights recent graphene-based biosen-
sors for PC protein biomarkers detection. As far as we 
know, this is the first review that focuses on specific one 
disease. We reviewed recent progress of graphene-based 
biosensors for PC protein biomarker detection. Our 
manuscript clearly stated the advantages and shortcom-
ings of most of the graphene-based when facing PC diag-
nosis, thus, the manuscript should be valuable for the 
future application of graphene-based biosensors.
Most commonly used protein biomarkers for PC 
detection
Protein biomarkers for cancer diagnosis are usually pro-
duced by either cancer cells or other cells in response 
to cancer [32–34], which have been proved to be prom-
ising targets for early diagnosis, monitoring treatment 
response, detecting recurrence or following up prognosis 
of cancer [35–37]. Protein biomarkers are usually in low 
abundance and unstable in body fluids, and thus, the spe-
cific detection of protein biomarkers is usually affected 
by the crude or complex environment [33, 38]. Thus, sen-
sitivity, specificity, and accuracy are basic requirements 
to consider for protein biosensor fabrication [39–41].
Prostate-specific antigen (PSA) [42], which is also called 
human kallikrein 3 (hK3 or KLK3), has been widely rec-
ognized in clinical application as one of the earliest found, 
serological PC biomarkers [43, 44]. The PSA value above 
4.0  ng/mL is usually considered as abnormal [45], thus, 
4.0 ng/mL of PSA is the internationally recognized thresh-
old value for PC occurrence [46, 47]. However, the specific-
ity of PSA is still limited [48], because higher PSA levels can 
also be found in benign conditions, such as benign prostatic 
hyperplasia (BPH) [49–51], and PSA could be produced by 
normal breast and breast cancer cells [48]. These limita-
tions indicate that PSA alone is not an appropriate surrogate 
marker for the diagnosis and screening of PC. Fortunately, 
several other protein PC biomarkers are developed.
Prostate-specific membrane antigen (PSMA) [52] is a 
type II transmembrane protein, and PSMA expression 
has been reported in benign prostatic hyperplasia and 
increased to higher lever in high-grade prostatic intraepi-
thelial neoplasia and prostatic adenocarcinoma [53]. 
Further, stronger PSMA expression correlates to malig-
nancy [54, 55]. The available research results suggest the 
potential clinical use for PSMA in PC patients. So far, the 
major PSMA clinical application has been in therapeu-
tics and imaging [56–58]. Prostate stem cell antigen [59] 
is another recently discovered PC biomarker [60], which 
is highly expressed by a large number of human prostate 
tumors, such as metastatic and hormone-refractory, but 
barely expressed in normal tissues [60–62]. Engrailed-2 
(EN2) protein is found in the urine sample of prostatic 
cancer patients and showed a specificity of 88.2% and a 
sensitivity of 66% [63, 64]. Therefore, the EN2 in urine is 
widely recognized as a potential biomarker of PC.
Properties of graphene materials in biosensor 
study
Graphene is a two-dimensional (2D) nanomaterial, which 
plays an important role in the biosensor field [64–66]. The 
use of graphene in biosensing platform offers remarkable 
physical, optical, electrochemical and magnetic properties 
[67–70]. Different kinds of graphene materials are researched 
in biosensors including pristine graphene and functionalized 
graphene such as graphene oxide (GO), reduced graphene 
oxide (rGO), and graphene-based quantum dots (GQDs), 
etc. [71–74]. Pristine graphene is identified as the array of 
a 2D hexagonal lattice of  sp2-bonded carbon atoms. GO is 
chemically produced by oxidation and exfoliation of gra-
phene, causing extensive oxidative modification of the basal 
plane [31, 75–77]. The rGO is prepared through reductive 
process of GO, for this purpose, different methods have been 
developed to reduce its oxygen content, including thermal, 
chemical, microwave, photochemical, microbial/bacterial, 
and photo-thermal methods [78–80]. GQDs consist of single 
to tens of layers of graphene with a size of a few nanometers 
which exhibit quantum phenomena [81, 82].
Development of protein biosensors based on graphene 
could be classified into two main groups (Fig. 1): Firstly, 
functioned graphene materials including GO, rGO and 
GQDs [72] were assembled onto the biosensor surface 
[electrode, field-effect transistors (FET) channel, etc.] to 
construct novel biosensor interfaces for improved assem-
bling of molecular receptors [83]. In this group, excellent 
biosensor performance was achieved mainly based on the 
increased specific surface area and the unique π–π orbital 
interaction on the interface. Secondly, many recent stud-
ies applied graphene materials as excellent carriers for 
the construction of novel nanocomposites [84], and in 
this group, interesting biosensor signal amplification and 
unique catalytic/chemical activity was realized for sensi-
tive protein biomarker analysis [85].
Biosensor interfaces based on graphene
Graphene and its derivatives are studied for the construc-
tion of novel biosensor interface [67], which is critical 
for interface-based biosensors including electrochemical 
biosensors, electrochemiluminescent (ECL) biosensors 
and FET biosensor [86]. Many recent studies reported 
that nanocomposites based on graphene showed 
improved capability of combining different biomolecules, 
with higher surface area [87] and excellent biocompat-
ibility [88].
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Construction of antibody‑graphene biosensor interface
Traditionally, antibodies are physically adsorbed onto the 
immune-assay surfaces, such as classic 96-well plates and 
colloidal gold test strips. However, one of the main obsta-
cles is the affinity and capacity, because the hydropho-
bic and hydrophilic interaction is relatively weak and the 
orientation of the antibody molecules is random [89]. As 
several recent studies reported, the strong cross-linking 
between carboxylic acid groups on graphene materials 
and the amine groups of antibodies (COOH-NH2) was 
used for the assembling of antibody on novel biosensor 
interfaces [90, 91]. In their work, the application of gra-
phene materials increased the loading amount, orienta-
tion controllability as well as binding capability of the 
antibodies or antibody fragments. For example, Li et  al. 
developed a graphene modified sensor platform with 
increased surface area, and then assembled antibody onto 
the surface through COOH–NH2 combining, with the 
assistant of 1-ethyl-3-(3-dimethylaminopropyl) carbodi-
imide (EDC) and N-hydroxysuccinimide (NHS), and they 
finally achieved a low detection limit of 2 pg/mL [92].
In order to realize better-oriented assembling of anti-
body, Mao et  al. applied chitosan as the dispersant to 
construct an immuno-interface on a glassy carbon 
electrode (Fig. 2A), which provided much more amino 
groups for PSA antibody bonding. They finally devel-
oped a simple, label-free electrochemical immunosen-
sor on graphene-methylene blue composite modified 
electrode [93]. More recently, Jang et  al. developed a 
novel 3D graphene-Au composite (Fig.  2B), toward 
increased accessible surface area for antibody combi-
nation than 2D graphene sheet. More importantly, the 
crumpled graphene could produce higher capacitances, 
which is crucial for the following electrochemical 
immunosensing [94].
A graphene-modified electrode was also reported in 
ECL biosensor [95] for PSA detection. More recently, 
Wu et  al. developed an electrode surface modified with 
Au/Ag–rGO (Fig. 3A), and then, a large amount of ami-
nated GQDs and carboxyl GQDs were combined onto 
the electrode surface. In their work, Au and Ag nanopar-
ticles were used for the adsorption of PSA antibody, and 
meanwhile, GQDs were for the ECL signal amplification. 
Finally, they constructed a label-free PSA ECL biosensor 
with a detection limit as low as 0.29 pg/mL [96].
Graphene materials were also applied in FET biosen-
sors, for the construction of 2D nano-FET biosensors 
[97–101], with unique advantages like more receptor bio-
molecules, low noise, and high sensitivity, compared with 
1D FET biosensors [102–104]. As a successful exam-
ple, Kim and coworkers [105] developed an rGO-based 
FET biosensor for label-free and ultrasensitive analysis 
of PSA/α1-antichymotrypsin (PSA-ACT) (Fig.  3B). The 
FET biosensor was produced by combining rGO onto 
an aminated glass surface, and then, functionalized with 
PSA antibody. When PSA-ACT was captured by the anti-
bodies on FET substrate, a linear shift of the gate voltage 
(ΔVg,min) was achieved, indicating the minimum conduc-
tivity. Finally, they successfully performed detection of 
PSA-ACT of femtomolar level.
Construction of aptamer‑graphene biosensor interface
For interface-based PC biosensors, the DNA cap-
ture probe plays a key role, which could recognize and 
Fig. 1 For prostate cancer detection, graphene materials are applied for the construction of novel interfaces and signal tags, on different analysis 
platforms including electrochemical, FET, fluorescence, colorimetric, ECL biosensors, et al
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Fig. 2 Schematic illustration of Label-free electrochemical immunosensors for PC protein biomarkers based on: A graphene-methylene blue 
nanocomposite, Reprinted with permission from [93], Copyright 2011 Elsevier. B graphene-Au nanocomposite (Reprinted with permission from 
[94]. Copyright 2014 Elsevier)
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capture the target molecules [106]. The very famous 
DNA probe in PC biosensor is DNA aptamer [10, 107–
109], which is a special single-strand DNA (ssDNA) 
isolated from DNA/RNA libraries of random sequence, 
by using an in  vitro selection process called systematic 
evolution of ligands by exponential enrichment (SELEX) 
[110–113].
As the first step toward an aptasensing platform, sci-
entists developed several different strategies to assem-
ble the DNA aptamer onto the electrode as the key 
recognition element [114–117]. In many reported studies, 
graphene-based nanocomposites were firstly prepared 
consisting of graphene and another combing material. 
For example, Bafrooei et  al. modified the electrode with 
rGOmulti-walled carbon nanotube (MWCNT) nanocom-
posite and then produced a layer of gold nanoparticles 
(AuNPs) through electrochemical reduction under − 0.2 V 
in  HAuCl4, then SH-labeled DNA aptamer was combined 
to Au on the electrode surface. Finally, their aptasensor 
achieved 1.0  pg/mL limit of detection (LOD) by using 
both DPV and ESI methods. Different chemical reactions 
were applied for the assembling of DNA onto graphene 
Fig. 3 Illustration of PSA immunosensor fabrication process. A An ECL immunosensor on the electrode surface modified with Au/Ag-rGO, 
Reprinted with permission from [96]. B FET immunosensor on an rGO channel (Reprinted with permission from [105]. Copyright 2012 Elsevier)
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materials. Branched polyethylenimine (PEI) was applied 
by Pan et al. to connect thiol-mediated ssDNA onto car-
boxylated GO for PSA detection [118]. Recently, EDC-
NHS coupling was applied by Settu et al. to combine DNA 
probe onto a screen-printed carbon-graphene-modified 




In 2010, Qu’s group firstly reported the peroxidase-like 
activity of GO (Fig. 4a) [120]. Before long, Yang and cow-
orkers found GO was capable of catalyzing the oxidation 
Fig. 4 a Schematic illustration of peroxidase-like activity of GO for the colorimetric detection of glucose, Reprinted with permission from [120], 
Copyright 2010, John Wiley and Sons, b schematic representation of the immunoassay procedure (Reprinted with permission from [134]. Copyright 
2010 Elsevier)
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of hydroquinone with the assistant of  H2O2, producing a 
brown color solution. Thus, they produced an antibody-
functionalized GO as the signal tag and developed a 
sandwich-type colorimetric immunoassay for the detec-
tion of PSA. In their work [121], an immunocomplex 
was established when PSA combined GO with second-
ary anti-PSA (GO-Ab2) and magnetic bead (MB) with 
primary anti-PSA antibody (MB-Ab1). After the sepa-
ration in a magnetic field, the color signal was detected 
corresponding to the concentration of PSA. Their simple 
immunoassay can be detected by naked eyes (Fig. 4b).
Graphene materials being applied as the carrier of signal 
tags
Many recent studies applied graphene-related materials 
as excellent carriers for the construction of novel nano-
composites for biosensor signal amplification [122–124]. 
These graphene-based composites were developed by 
combining graphene or its derivates with metal oxides, 
metal nanoparticles, or conductive polymers, etc., 
and this kind of composites showed unique catalytic/
chemical activity [86], that has been widely applied in PC 
biosensors [125].
Han et al. developed a novel signal tag for PSA and free 
PSA (fPSA) detection, by using onion-like mesoporous 
graphene sheets (O-GS) as the carrier of different AuNP-
based nanohybrids [126]. As the novel O-GS have mul-
tilayer lamellar structure, large surface-to-volume ratio, 
and excellent electronic transport properties, two kinds 
of redox nanocomposites were attached to the surface of 
O-GS, which could accelerate the electron transfer rate 
and enhance the immobilization amount of enzyme and 
detection antibodies. Sun et al. reported a signal label by 
combining bovine serum albumin (BSA)-stabilized silver 
nanoparticles onto ZnO nanorods modified rGO, and 
the AgNPs in the composite showed super catalytic per-
formance toward hydrogen peroxide  (H2O2), generating 
a current signal [127]. Feng et al. developed a sandwich-
type electrochemical immunosensor for the detection 
of PSA. In their work, a GO platform (Au@Th/GO) 
was used to immobilize primary antibodies and acceler-
ate the electron transfer on the electrode interface. An 
Fig. 5 Protein capture and detection mediated by  Fe3O4@GO sheets. Proteins captured by  Fe3O4@GO decorated with detection antibodies. 
Composite with biomarker was then captured on the sensor surfaces coated with graphene and capture antibodies. Amperometric signal was 
generated by injecting 100 μL 5 mM  H2O2 (Reprinted with permission from [129]. Copyright 2016 Elsevier)
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rGO-based nanocomposite (PtCu@rGO/g–C3N4) with 
large surface area, good biocompatibility, and excellent 
conductivity were used as labels for combining second-
ary antibodies and amplifying signals. Then secondary 
antibodies were combined onto this platform and signals 
were amplified from  H2O2 reduction [128].
Sharafeldin et  al. [129] assembled  Fe3O4 nanoparti-
cles together with antibody onto GO sheets to produce 
a multi-function nanocomposite (Fig. 5). When the GO-
antibody-Fe3O4 nanocomposite specifically combined to 
PSA and PSMA proteins, the resulted complex could be 
isolated in a magnetic field and delivered in microfluidic 
channel to an electrochemical detection cell. The  Fe3O4–
GO particles subsequently catalyze  H2O2 reduction, gen-
erating a current signal. Improved LOD of 15  fg/mL of 
PSA and 4.8  fg/mL of PSMA was achieved, which was 
1000-times better than previously reported PSA biosen-
sors using  Fe3O4 only, probably because GO carried more 
 Fe3O4 particles and thus dramatically increased the elec-
trochemical signal.
Conclusion and future perspectives
Biosensors for cancer biomarker detection opened a 
new avenue for the POC PC detection. In spite of their 
very short history, graphene-based materials have suc-
cessfully demonstrated their unique advantages in bio-
sensors for PC protein biomarkers. This review has 
summarized recent advances, challenges, and trends 
in the application of graphene-based materials for bio-
sensing of PC protein biomarkers. In this review, the 
commonly used PC protein biomarkers for biosensor, 
the unique properties of graphene and the roles of gra-
phene-based materials for biosensing were introduced. 
Among various PC protein biomarkers, PSA was the 
most frequently selected target for PC detection bio-
sensor construction. Most studies focused on single 
biomarker detection and studies on detection of multi-
ple biomarkers are limited. A variety of graphene-based 
materials such as pristine graphene, functionalized gra-
phene (GO, rGO, GODs) were used in PC biosensor 
development and most of them were combined with 
other nanomaterials like nanoparticles. We have also 
summarized various strategies and approaches which 
can be used for graphene-based biosensor develop-
ment. Graphene-based materials were used not only 
for novel biosensor interfaces construction but also as 
excellent carriers for the construction of novel nano-
composites for signal amplification. In most of the 
cases, graphene-based biosensors have exhibited satis-
factory biocompatibility towards the bioactive species 
and remarkable performance with high sensitivities, 
wide linear detection ranges, low detection limits and 
long-term stabilities (Table  1). As other 2D materi-
als have now been explored, we believe that more 2D 
Table 1 Current generation reports of graphene‑based biosensors for PC biomarker detection
Technique Receptor system Target proteins LOD Detection ranges References
ECHEM rGO-MWCNT/AuNPs PSA 1.0 pg/mL (0.005–20) ng/mL for DPV, (0.005-
100) ng/mL for EIS
[132]
ECHEM rGO/Ag@BSA HCG, PSA, CEA 0.0007 mIU/mL for HCG, 0.35 pg/
mL for PSA, and 0.33 pg/mL 
for CEA
(0.002-120) mIU/mL for HCG, 
(0.001–110) ng/mL for PSA, 
(0.001–100) ng/mL for CEA
[127]
ECHEM Au@Th/GO, PtCu@rGO/graphitic 
carbon nitride
PSA 16.6 fg/mL 50 fg/mL–40 ng/mL [128]
ECHEM GO/ssDNA/PLLA NPs VEGF, PSA – (0.05-100) ng/mL for VEGF, 
(1-100) ng/mL for PSA
[118]
ECHEM Fe3O4/PDDA/GO PSA, PSMA 15 fg/mL for PSA, 4.8 fg/mL for 
PSMA
(61 fg/mL–3.9 pg/mL) for PSA, 




fPSA, PSA 6.7 pg/mL for fPSA, 3.4 pg/mL 
for PSA
(0.02–10) ng/mL for fPSA, 
(0.01–50) ng/mL for PSA
[126]
ECHEM GS/DA/Fe3O4/FC PSA 2 pg/mL (0.01–40) ng/mL [92]
ECHEM Carbon-graphene/aptamer EN2 protein 38.5 nM (35–185) nM [119]
ECHEM GS-MB-CS PSA 13 pg/mL (0.05–5.00) ng/mL [93]
ECHEM 3D graphene/Au PSA 0.59 ng/mL (0–10) ng/mL [94]
FET rGO PSA-ACT 100 fg/mL (10−7–1) μg/mL [105]
Fluorescence GQDs–NR ACP 28 μU/mL (0–1500) μU/mL [133]
Fluorescence GO/peptide/FITC PSA 0.3 nM (0–20) nM [64]
ECL Au/Ag-rGO/aminated-GQDs/
carboxyl-GQDs
PSA 0.29 pg/mL 1 pg/mL–10 ng/mL [96]
ECL graphene PSA 8 pg/mL 10 pg/mL–8 ng/mL [95]
Colorimetric GO/MB PSA – – [134]
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materials like  MoS2 could be employed and integrated 
into biosensors for PC biomarker detection in the 
upcoming future.
Although tremendous progress has been made in the 
past a few years of graphene-based biosensors for PC 
detection, there still remain some challenges. Firstly, 
PSA has been demonstrated not a specific biomarker 
in prostate cancer early screening. As a result, detec-
tion of multiple biomarkers is crucial for precise diag-
nosis and prognosis of PC [130, 131]. More attention 
should be paid to studies on the simultaneous detection 
of multiple biomarkers in the future. In addition, there 
are only a few studies on PC biomarker detection in dif-
ferent body fluid. To improve the accuracy and practi-
cability of the diagnosis, more studies are expected to 
perform biomarker detection in different body fluid.
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